CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
+7.53%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$1.07B
AUM Growth
+$162M
(+18%)
Cap. Flow
+$137M
Cap. Flow
% of AUM
12.79%
Top 10 Holdings %
Top 10 Hldgs %
37.33%
Holding
532
New
105
Increased
323
Reduced
47
Closed
36
Top Buys
| 1 |
Apple
AAPL
|
$9.9M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$7.06M |
| 3 |
NVIDIA
NVDA
|
$6.46M |
| 4 |
Microsoft
MSFT
|
$6.23M |
| 5 |
ProShares Ultra Gold
UGL
|
$5.73M |
Top Sells
| 1 |
Alibaba
BABA
|
$5.72M |
| 2 |
GSK
GSK
|
$5.14M |
| 3 |
Pinduoduo
PDD
|
$3.46M |
| 4 |
Procter & Gamble
PG
|
$2.91M |
| 5 |
Synopsys
SNPS
|
$2.45M |
Sector Composition
| 1 | Technology | 38.06% |
| 2 | Healthcare | 25.43% |
| 3 | Consumer Discretionary | 12.38% |
| 4 | Communication Services | 10.24% |
| 5 | Financials | 3.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
251
Microchip Technology
MCHP
$35.6B
| $501K | 0.05% |
8,739
+1,934
| +28% | +$111K |
|
252
Arrowhead Research
ARWR
$4.02B
| $496K | 0.05% |
26,385
+2,475
| +10% | +$46.5K |
|
253
Protagonist Therapeutics
PTGX
$3.77B
| $488K | 0.05% |
12,637
+1,308
| +12% | +$50.5K |
|
|
ANSS
254
DELISTED
Ansys
ANSS
| $480K | 0.04% |
1,423
+315
| +28% | +$106K |
|
255
Iovance Biotherapeutics
IOVA
$901M
| $478K | 0.04% |
64,625
+6,249
| +11% | +$46.2K |
|
256
CoStar Group
CSGP
$37.9B
| $478K | 0.04% |
6,672
+1,474
| +28% | +$106K |
|
257
IDEAYA Biosciences
IDYA
$2.38B
| $471K | 0.04% |
18,327
+2,078
| +13% | +$53.4K |
|
258
Geron
GERN
$893M
| $454K | 0.04% |
128,176
+12,239
| +11% | +$43.3K |
|
259
Zscaler
ZS
$42.7B
| $450K | 0.04% |
2,497
+580
| +30% | +$105K |
|
260
Tarsus Pharmaceuticals
TARS
$2.43B
| $449K | 0.04% |
8,106
+789
| +11% | +$43.7K |
|
261
Beam Therapeutics
BEAM
$2.11B
| $441K | 0.04% |
17,794
+1,707
| +11% | +$42.3K |
|
262
ON Semiconductor
ON
$20.1B
| $437K | 0.04% |
6,929
+1,496
| +28% | +$94.3K |
|
263
Apogee Therapeutics
APGE
$2.26B
| $432K | 0.04% |
9,547
+892
| +10% | +$40.4K |
|
264
Ligand Pharmaceuticals
LGND
$3.25B
| $429K | 0.04% |
4,007
+493
| +14% | +$52.8K |
|
265
Warner Bros
WBD
$30B
| $422K | 0.04% |
39,923
+8,823
| +28% | +$93.3K |
|
266
Mirum Pharmaceuticals
MIRM
$3.82B
| $421K | 0.04% |
10,179
+1,003
| +11% | +$41.5K |
|
267
Harmony Biosciences
HRMY
$2.07B
| $416K | 0.04% |
12,093
+1,162
| +11% | +$40K |
|
268
Akero Therapeutics
AKRO
$3.58B
| $412K | 0.04% |
14,800
+1,446
| +11% | +$40.2K |
|
269
CG Oncology
CGON
$2.52B
| $411K | 0.04% |
+14,340
| New | +$411K |
|
270
Tenet Healthcare
THC
$17.3B
| $410K | 0.04% |
+3,250
| New | +$410K |
|
271
Carnival Corp
CCL
$42.8B
| $405K | 0.04% |
16,248
+7,631
| +89% | +$190K |
|
272
Disc Medicine
IRON
$2.11B
| $400K | 0.04% |
6,310
+593
| +10% | +$37.6K |
|
273
Agios Pharmaceuticals
AGIO
$2.09B
| $397K | 0.04% |
12,092
+1,150
| +11% | +$37.8K |
|
274
GlobalFoundries
GFS
$18.5B
| $386K | 0.04% |
8,994
+1,998
| +29% | +$85.7K |
|
275
Amphastar Pharmaceuticals
AMPH
$1.37B
| $379K | 0.04% |
10,195
+833
| +9% | +$30.9K |
|